Patents Examined by Shanon A. Foley
  • Patent number: 11028151
    Abstract: Amino acid sequences are provided that are directed against/and or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: June 8, 2021
    Assignee: Ablynx N.V.
    Inventors: Erik Depla, Catelijne Stortelers, Stephanie Staelens
  • Patent number: 11020475
    Abstract: Disclosed is cold-adapted live attenuated severe acute respiratory syndrome coronavirus (SARS-CoV-2) prepared by infecting cells with severe acute respiratory syndrome coronavirus and then adapting the severe acute respiratory syndrome coronavirus to a temperature from 37° C. to 22° C. in a step by step manner. Further, a vaccine containing the cold-adapted live attenuated severe acute respiratory syndrome coronavirus (SARS-CoV-2) is disclosed.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: June 1, 2021
    Assignee: The Industry & Academic Cooperation in Chungnam National University (IAC)
    Inventors: Sang-Heui Seo, Yun-Yueng Jang
  • Patent number: 11020471
    Abstract: The present invention provides exosomes isolated from an animal, wherein the animal (a) has overcome a disease caused by a pathogen, and (b) it is free from the pathogen that causes the diseases. The invention also provides process for obtaining these exosomes and the use thereof in therapy.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: June 1, 2021
    Assignees: INNOVEX THERAPEUTICS, S.L., INSTITUCIÓ CATALANA DE RECERCA | ESTUDIS AVANCATS, FUNDACIÓ PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA (ISGLOBAL), FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÉNCIES DE LA SALUT GERMANS TRIAS | PUJOL, UNIVERSITAT DE LLEIDA
    Inventors: Hernando Antonio Del Portillo Obando, Francisco Enrique Borrás Serres, Lorenzo José Fraile Sauce, Sergio Roberto Montaner Tarbes, Maria Montoya González
  • Patent number: 11021531
    Abstract: This disclosure provides antibodies and antigen-binding fragments that are derived from 2ghw and that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments provided herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments provided herein can be used to diagnose a SARS-Cov-2 infection.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: June 1, 2021
    Assignee: Centivax, Inc.
    Inventors: Jacob Glanville, Shahrad Daraeikia, I-Chieh Wang, Sindy Andrea Liao-Chan, Jean-Philippe Bürckert, Sawsan Youssef
  • Patent number: 11021520
    Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode an RSV immunogen are disclosed. Nucleic acids are disclosed that comprise the sequences that encodes consensus RSV F protein or immuno-genic fragment thereof, sequences that encodes an RSV G(A) protein or immunogenic fragment thereof and sequences that encodes an RSV G(B) protein or immunogenic fragment thereof. Compositions comprising one, combinations of two or all three sequences are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Nucleic acid molecules and compositions comprising the chemokine CC20 and/or a consensus RSV M2-1 protein or immunogenic fragment thereof are also disclosed. Immunomodulatory methods and methods of inducing an immune response against RSV are disclosed. Methods of preventing RSV infection and methods of treating individuals infected with RSV are disclosed.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: June 1, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Daniel Choo, Kar Muthumani, Nyamekye Obeng-Adjei, Veronica Scott
  • Patent number: 11020470
    Abstract: Provided herein are membrane enveloped virus-like particles (VLPs), and methods of use and synthesis thereof. In particular, yeast-cell-derived VLPs are provided that comprise surface-displayed glycoproteins and/or multiple virally-derived proteins.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: June 1, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Fei Wen, Eshita Khera, Brett Dallas Hill, Syed Rizvi
  • Patent number: 11021532
    Abstract: This disclosure provides superhuman antibodies and antigen-binding fragments that can be administered to an individual that is infected or suspected of being infected with a virus. Superhuman antibodies and antigen-binding fragments provided herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to at least several weeks. Superhuman antibodies and antigen-binding fragments provided herein can be used to diagnose a SARS Cov-2 infection.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: June 1, 2021
    Assignee: Centivax, Inc.
    Inventors: Jacob Glanville, Shahrad Daraeikia, I-Chieh Wang, Sindy Andrea Liao-Chan
  • Patent number: 11015179
    Abstract: The present specification relates to an anti-viral composition and, more particularly, to a composition that both is anti-viral and prevents and treats diseases associated with viruses, containing a peptide derived from a telomerase, thereby being effective in treating and preventing diseases associated with viruses and pathological symptoms caused by viruses. The peptide exhibits an effect of treating diseases associated with viruses by inhibiting the RNA replication of viruses, thereby being capable of providing a method that both is antiviral and prevents and treats diseases associated with viruses.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: May 25, 2021
    Assignee: GemVax & KAEL Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 11013798
    Abstract: The present invention is directed to novel vaccine delivery platform based on the Orf virus (ORFV) genome, which carry heterologous antigens, methods of making and methods of using the same for prevention of infections, diseases, and other conditions in animals.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: May 25, 2021
    Assignees: South Dakota Board of Regents, Federal University of Santa Maria
    Inventors: Diego G. Diel, Eduardo F. Flores
  • Patent number: 11013794
    Abstract: The present application relates to a method for preparing a foot-and-mouth disease (FMD) vaccine, comprising the following steps: (i) obtaining cell culture media containing FMD virus; (ii) separating and purifying the cell culture media containing FMD virus by an integrated filtration system with two membranes in combination; and (iii) collecting the concentrated solution containing FMD virus obtained in step (ii). The present application also relates to an FMD vaccine prepared by the method described herein and use thereof in the manufacture of a medicament for preventing animal FMD. The present application further relates to an apparatus for preparing an FMD vaccine, which comprises an integrated filtration system with two membranes in combination.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: May 25, 2021
    Inventors: Guijun Ma, Zhen Zhang, Dongsheng Nie, Panqi Luo
  • Patent number: 11008564
    Abstract: Polynucleotide constructs that express an engineered foot-and-mouth disease (FMDV) P1 precursor protein and a non-FMDV TEV protease and methods for safe and efficient recombinant production of FMDV antigens and immunogens. Recombinant production of FMDV antigens avoids the need to culture highly-infectious FMDV, while conventional culture methods for producing FMDV antigens rely on the native FMDV 3C protease which exerts toxic effects on host cells. The inventors have developed a new system that efficiently and safely processes FMDV P1 precursor without the FMDV 3C protease, thus avoiding the toxic effects associated with use of the 3C protease. The invention is also directed to the FMDV antigens and virus-like particles produced by this system as well as to FMDV vaccines, diagnostics and other biologics.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: May 18, 2021
    Assignee: The Government of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max Rasmussen
  • Patent number: 11000585
    Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: May 11, 2021
    Assignee: Phibro Animal Health Corporation
    Inventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
  • Patent number: 10980873
    Abstract: The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumour or cancer conditions, and for the preparation of agents or compositions for such treatment.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: April 20, 2021
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTES
    Inventors: Frédéric Tangy, Marc Gregoire, Jean-François Fonteneau, Jean-Baptiste Guillerme, Chantal Combredet
  • Patent number: 10983125
    Abstract: Provided are a marker for detecting a highly pathogenic influenza virus including a protein mutant prepared by substituting the amino acids 68 and 69 of a PB1-F2 protein, a composition for detecting a highly pathogenic virus including an agent for measuring the protein mutant, and a detection kit including the same, a method for detecting a highly pathogenic virus including measuring the protein mutant, an antiviral composition against influenza A virus including an inhibitor of binding between a PB1-F2 protein in which the amino acids 68 and 69 are substituted and DDX3, and a method for screening an antiviral substance against influenza A virus.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: April 20, 2021
    Assignee: Dandi Bioscience Inc
    Inventors: Kyun-Hwan Kim, Eun Sook Park, Yeong-Min Park, Baik Lin Seong, Young Ho Byun, Hye Min Lee
  • Patent number: 10982221
    Abstract: The present invention describes the plant-based production of a therapeutic anti-virus antibody.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: April 20, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Qiang Chen, Huafang Lai, Jonathan Hurtado
  • Patent number: 10973899
    Abstract: The invention provides, inter alia, improved replicons and vectors encoding them, where the replicons provide sustained expression of an encoded protein. These replicons comprise flavivirus replicases and heterologous protein coding sequences, wherein the heterologous protein coding sequences are flanked by separation sequences for improved efficacy. These nucleic acids provided by the invention, including self-replicating RNAs provided by the invention, are useful in methods of protein expression, such as for vaccines (e.g., for methods of immunization), as well as expression of therapeutic proteins, such as antibodies (e.g., for methods of treatment).
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: April 13, 2021
    Assignee: Novartis AG
    Inventors: Caitlin Jeanette Hagen, Dong Yu, Peter W. Mason, Peter Shahinian
  • Patent number: 10967014
    Abstract: The invention relates to pneumoviral virions comprising a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion. The invention also relates to methods for producing the pneumoviral virions and for using the virions in the treatment or prevention of pneumoviral infection and disease. A preferred pneumoviral virion is a virion of Respiratory Syncytial Virus in which preferably the gene for the G attachment protein is inactivated and complemented in trans.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: April 6, 2021
    Assignee: De Staat der Nederlanden, vert. door de minister van VWS
    Inventors: Willem Luytjes, Myra Noorely Widjojoatmodjo
  • Patent number: 10967058
    Abstract: Compositions for prevention of Foot and Mouth Disease (FMD) are provided, comprising an antigen component in the amount equivalent to 0.5-20 ?g FMD virus and an adjuvant component comprising oil, an immunostimulatory oligonucleotide, and a polycationic carrier. Methods of using the composition, as well as the methods of reducing FMD persistence are also provided.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: April 6, 2021
    Assignees: Zoetis Services LLC, United States of America, as represented by the Secretary of Agriculture
    Inventors: Paul Joseph Dominowski, John Morgan Hardham, James Alan Jackson, Cyril Gerard Gay, Luis Leandro Rodriguez, Peter William Krug, Aida Elizabeth Rieder
  • Patent number: 10961281
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: March 30, 2021
    Inventors: Luis Alejandro Hernandez, Christine Margaret Muehlenthaler, Eric Martin Vaughn, Gregory Haiwick
  • Patent number: 10953088
    Abstract: The present invention is directed to novel immunogenic compositions that protect swine from disease caused by porcine epidemic diarrhea virus (PEDV). The present invention is also directed to novel immunogenic compositions that protect swine from disease caused by porcine deltacoronavirus (PDCoV), alone or as combination vaccine to protect against PEDV. The compositions of the invention provide killed viruses whose effectiveness is enhanced by the selection of preferred adjuvants. Novel culture methods are also employed to increase reproducible yield of cultured viruses. Live vaccines are also provided from the Calaf14 PEDV isolate.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: March 23, 2021
    Assignee: Zoetis Services LLC
    Inventors: Jacqueline Gayle Marx, John Morgan Hardham, Paul J. Dominowski, Vicki Jon Rapp Gabrielson, Monica Balasch Sanuy, Marta Cabana Sumsi, Laia Plaja Dilme, Alicia Urniza Hostench, Oscar Romero Galindo